Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma
Open Access
- 8 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 21 (1), 1-7
- https://doi.org/10.1186/s12885-021-08103-0
Abstract
Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibility of serial non-invasive mutational profiling of tumors. Combining tumor tissue and ctDNA analysis may increase the detection rate of mutations. This study aimed to evaluate the frequency of the CTNNB1 p.T41A mutation in ctDNA and tumor samples from HCC patients and to evaluate the concordance rates between plasma and tissue. We further evaluated changes in ctDNA after various HCC treatment modalities and the impact of the CTNNB1 p.T41A mutation on the clinical course of HCC. We used droplet digital PCR to analyze plasma from 95 patients and the corresponding tumor samples from 37 patients during 3 years follow up. In tumor tissue samples, the mutation rate was 8.1% (3/37). In ctDNA from HCC patients, the CTNNB1 mutation rate was 9.5% (9/95) in the pre-treatment samples. Adding results from plasma analysis to the subgroup of patients with available tissue samples, the mutation detection rate increased to 13.5% (5/37). There was no difference in overall survival according to CTNNB1 mutational status. Serial testing of ctDNA suggested a possible clonal evolution of HCC or arising multicentric tumors with separate genetic profiles in individual patients. Combining analysis of ctDNA and tumor tissue increased the detection rate of CTNNB1 mutation in HCC patients. A liquid biopsy approach may be useful in a tailored therapy of HCC.Keywords
Funding Information
- Kræftens Bekæmpelse (R133-A8404)
- Health Research Fund of Central Denmark Region (A951)
- Einar Willumsen Foundation (Ref 6000073)
This publication has 24 references indexed in Scilit:
- TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinomaScandinavian Journal of Gastroenterology, 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaThe New England Journal of Medicine, 2020
- Advances in molecular classification and precision oncology in hepatocellular carcinomaJournal of Hepatology, 2020
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular CarcinomaCancer Discovery, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular CarcinomaGastroenterology, 2019
- Molecular therapies and precision medicine for hepatocellular carcinomaNature Reviews Clinical Oncology, 2018
- Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesisNature Communications, 2017
- Genomic and Epigenomic Heterogeneity of Hepatocellular CarcinomaCancer Research, 2017
- Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progressionJournal of Hepatology, 2016